| Literature DB >> 35003081 |
Richard Felix Kraus1, Michael Andreas Gruber1.
Abstract
Neutrophils (polymorphonuclear cells; PMNs) form a first line of defense against pathogens and are therefore an important component of the innate immune response. As a result of poorly controlled activation, however, PMNs can also mediate tissue damage in numerous diseases, often by increasing tissue inflammation and injury. According to current knowledge, PMNs are not only part of the pathogenesis of infectious and autoimmune diseases but also of conditions with disturbed tissue homeostasis such as trauma and shock. Scientific advances in the past two decades have changed the role of neutrophils from that of solely immune defense cells to cells that are responsible for the general integrity of the body, even in the absence of pathogens. To better understand PMN function in the human organism, our review outlines the role of PMNs within the innate immune system. This review provides an overview of the migration of PMNs from the vascular compartment to the target tissue as well as their chemotactic processes and illuminates crucial neutrophil immune properties at the site of the lesion. The review is focused on the formation of chemotactic gradients in interaction with the extracellular matrix (ECM) and the influence of the ECM on PMN function. In addition, our review summarizes current knowledge about the phenomenon of bidirectional and reverse PMN migration, neutrophil microtubules, and the microtubule organizing center in PMN migration. As a conclusive feature, we review and discuss new findings about neutrophil behavior in cancer environment and tumor tissue.Entities:
Keywords: NEtosis; bidirectional (trans)migration; chemotactic gradients; extracellular matrix (ECM); microtubule organization center; neutrophil (PMN) function; neutrophil extravasation; tumor association
Mesh:
Substances:
Year: 2021 PMID: 35003081 PMCID: PMC8732951 DOI: 10.3389/fimmu.2021.767175
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
Figure 1Segmented neutrophil granulocytes in Pappenheim‐stained blood cell smears (graphic provided by the laboratory for Paediatric Oncology and Haematology at the University Medical Centre Regensburg).
Figure 2Life cycle of a neutrophil cell. Approximately 1011 PMNs are generated in the bone marrow via granulopoiesis every day. Attracted by cytokines, PMNs are consecutively released into the blood stream and thus into systemic circulation. At the sites of inflammation, PMNs leave the blood vessels through the endothelium, a process known as extravasation. In inflammatory human tissue, PMNs migrate along chemotactic gradients in the interstitium and perform specific neutrophil immune functions as a first line defense of the innate immune system.
Important inflammatory mediators and associated cell types..
| Mediator | Human | Origin of mediators | Receptor | Affected cell type | Literature source |
|---|---|---|---|---|---|
| Systematic | |||||
|
| |||||
|
|
| Monocytes, |
| Neutrophils, | ( |
|
|
| fibroblasts, | naive T-cells, | ||
|
|
| endothelium | fibroblasts | ||
|
|
| Epithelial cells, |
| Neutrophils, monocytes, | ( |
| eosinophils | microvascular or endothelial cells | ||||
|
|
| Macrophages, epithelial cells, mesenchymal cells |
| Neutrophils, monocytes, microvascular or endothelial cells | ( |
|
|
| Platelets |
| Neutrophils, | ( |
| NK cells | mesenchymal stem cells | ||||
|
|
| Monocytes, |
| Neutrophils, | ( |
| macrophages, |
| naive T-cells, | |||
| fibroblasts, | monocytes | ||||
| epithelial cells, | |||||
| endothelial cells | |||||
|
|
| Monocytes, |
| Monocytes, | ( |
| macrophages, | NK and T-cells, | ||||
| fibroblasts, | basophils, | ||||
| keratinocytes | dendritic cells | ||||
|
|
| Monocytes, |
| Monocytes, | ( |
| T cells, |
| NK and T-cells, | |||
| fibroblasts, |
| basophils, | |||
| mast cells | dendritic cells | ||||
|
|
| Monocytes, |
| Monocytes, | ( |
| macrophages, |
| NK and T-cells, | |||
| neutrophils, |
| dendritic cells | |||
| endothelium | |||||
|
|
| T-cells, |
| Monocytes, | ( |
| endothelium, |
| NK and T-cells, | |||
| platelets |
| basophils, | |||
| eosinophils, | |||||
| dendritic cells | |||||
|
|
| Peripheral blood, mononuclear cells |
| Neutrophils, | ( |
|
| monocytes, dendritic cells, T-cells | ||||
|
| |||||
|
|
| Bone-marrow-derived stromal cells, mesenchymal cells |
| Widely expressed | ( |
|
|
| Monocytes, microglial cells, endothelium |
| Macrophages, endothelial cells, smooth-muscle cells, T-cells | ( |
|
| |||||
|
| Liver cells |
| Platelets, neutrophils, eosinophils, monocytes, macrophages, dendritic cells, mast cells, lymphocytes, cardiomyocytes, astrocytes, microglia, neural stem cells, oligodendrocytes, synoviocytes, articular chondrocytes, hepatic kupffer cells, stimulated hepatocytes, keratinocytes | ( | |
| Cells of renal glomerulum, mesangium, | |||||
| endothelium, bronchial epithelium | |||||
|
| Neutrophils, macrophages, immature dendritic cells | ( | |||
| Specific T-cell subsets | |||||
| Cells of bone marrow, adrenal gland, spinal cord, thyroid, liver, lungs, spleen, brain and heart | |||||
| Adipocytes, skin fibroblasts | |||||
|
| Liver cells |
| Neutrophils, T-cells Dendritic cells | ( | |
| NK cells, mast cells, | |||||
| monocytes/macrophages, | |||||
| tubular epithelium, glomerular podocytes | |||||
|
| Invading pathogens, |
| Neutrophils, monocytes, macrophages, (myo)fibroblasts, | ( | |
| dead and dying host cells (passive release of mitochondrial formylated peptides) | cells of bronchial or colonic epithelium | ||||
|
| Liberated from ECM collagen |
| Neutrophils, | ( | |
| cells of bronchial epithelium | |||||
|
| Neutrophils, |
| Neutrophils, eosinophils, | ( | |
| cells of skin, lungs, and gut epithelium, mast cells, lymphocytes, monocytes | T-cells, mast cells | ||||
|
| Monocyte/macrophages, dendritic cells, B−cells, neutrophils, eosinophils, |
| Neutrophils, monocytes, T-cells | ( | |
| Basophils mast cells | |||||
|
| |||||
|
| Derived from arachidonic acid released from phospholipids in cellular membranes |
| Neutrophils, macrophages, eosinophils, T-cells, epithelial/endothelial cells, fibroblasts, smooth muscle cells | ( | |
|
| Derived from arachidonic acid released from phospholipids in cellular membranes |
| Neutrophils, T-cells, platelets, macrophage-lineage cells (M0, Kupffer cells and microglia), thoracheal cells of epithelium, endothelium, myometrium | ( | |
Figure 3Schematic illustration of the extravasation process: PMNs leaving a blood vessel through the endothelium. The first step of the multi-stage process is the weak binding of PMNs to the endothelium due to interactions between selectins induced on endothelial cells and their corresponding ligands on the PMNs. In this figure, the process is illustrated for E-selectin and its ligand ESL-1 [containing sialyl-Lewisx-unit (s-Lex)]. However, such binding is not strong enough to resist the shear forces of the blood flow, so that new bondages are continuously formed and released again (rolling). Stronger interactions are only induced, however, when a chemokine (such as CXCL-8) binds to its specific receptor (not shown) on the neutrophil cell, which triggers the activation of the integrins LFA-1 and CR-3 (Mac-1) (firm adhesion). To induce the expression of adhesion molecules [such as ICAM-1 (ligand of LFA-1)] on the endothelium, inflammation-specific cytokines such as TNF-α are additionally required. Strong binding between ICAMs and integrins terminates rolling (arrest) and allows PMNs to squeeze between the endothelial cells (paracellular transmigration); yet, a transcellular way of transmigration is also possible as described in the literature. The neutrophil cell then crosses the basement membrane with the help of matrix metalloproteinases (like MMP-9), which are expressed on the neutrophil cell surface. Finally, the extravasated PMN migrates along a concentration gradient of chemokines secreted by cells at the sites of infection in the interstitium (4, 32).
Important receptors and corresponding ligands involving neutrophil adhesion and signaling..
| Tissue | Receptor Family | Receptor | Cell Type of Receptor | Ligand on Neutrophils | Literature Source | |
|---|---|---|---|---|---|---|
|
| ||||||
|
| Selectins |
| Activated endothelium, platelets |
| ( | |
|
| ||||||
|
| Activated endothelium |
| ( | |||
|
| Activated endothelium |
| ( | |||
|
|
| |||||
|
| Selectins | Platelet-dependent: | Activated endothelium, platelets |
| ( | |
|
| ||||||
|
| ||||||
| Immunoglobulin superfamily |
| Activated endothelium | P-Selectin dependent: | ( | ||
|
| Selectins |
| Platelets |
| ( | |
|
| Activated endothelium, |
| ( | |||
| platelets | ||||||
| ? |
| ( | ||||
| (CD62L) | ||||||
|
| ||||||
|
| Immunoglobulin superfamily |
| Activated endothelium, activated leukocytes | PSGL-1-induced: | ( | |
| Selectins |
| Activated endothelium |
| ( | ||
|
|
| |||||
|
| ? | ? | ( | |||
|
| Immunoglobulin superfamily |
| Activated endothelium, activated leukocytes | PSGL1-induced: | ( | |
|
| ||||||
|
| Immunoglobulin superfamily |
| Activated endothelium, activated leukocytes |
| ( | |
|
| Activated endothelium |
| ( | |||
|
| Immunoglobulin superfamily |
| Activated endothelium, activated leukocytes |
| ( | |
| Glucosamino-glycan |
| Activated endothelium |
| ( | ||
| Enzyme (Peptidase) |
| Activated endothelium |
| ( | ||
|
| Immunoglobulin superfamily |
| Activated endothelium, activated leukocytes |
| ( | |
|
| Immunoglobulin superfamily |
| Activated endothelium, activated leukocytes |
| ( | |
|
| Activated endothelium |
| ( | |||
| Enzyme (Peptidase) |
| Activated endothelium |
| ( | ||
|
| ||||||
|
| Immunoglobulin superfamily |
| Activated endothelium, activated leukocytes |
| ( | |
|
| Immunoglobulin superfamily |
| Activated endothelium, activated leukocytes |
| ( | |
| CD11a/CD18); | ||||||
|
| ||||||
|
| Immunoglobulin superfamily |
| Activated/resting endothelium, activated leukocytes, dendritic cells (ICAM-2) |
| ( | |
| CD11a/CD18); | ||||||
|
| ||||||
|
| Immunoglobulin superfamily |
| Activated endothelium, activated leukocytes |
| ( | |
|
| ||||||
|
| Immunoglobulin superfamily |
| Activated endothelium |
| ( | |
|
| Activated/resting endothelium, activated leukocytes |
| ( | |||
| CD11a/CD18); | ||||||
|
|
| |||||
|
| Activated leukocytes, endothelial cell-cell junctions |
| ( | |||
|
| Activated endothelium |
| ( | |||
|
| Junctions at interendothelial contacts |
| ( | |||
|
| Junctions at interendothelial contacts |
| ( | |||
| Membrane glycoprotein |
| Activated endothelium, activated leukocytes |
| ( | ||
|
| Activated leukocytes, cell contact between endothelial cells |
| ( | |||
| Calcium-dependent transmembrane glycoprotein |
| Activated/resting Endothelium | Between endothelial cells | ( | ||
| Glucosamino-glycan |
| Activated/resting endothelium |
| ( | ||
|
| Immunoglobulin superfamily |
| Activated endothelium, activated leukocytes |
| ( | |
|
| Immunoglobulin superfamily |
| Activated leukocytes, endothelial cell-cell junctions |
| ( | |
|
| Calcium-dependent transmembrane glycoprotein |
| Activated/resting Endothelium | Between endothelial cells | ( | |
| Immunoglobulin superfamily |
| Activated endothelium |
| ( | ||
|
| Junctions at interendothelial contacts |
| ( | |||
Comment on : The classical cascade refers to neutrophils extravasating in postcapillary venules; in some organs, however, extravasation can take place in different vessels. In the liver, brain, and lungs, some steps of the classical cascade do not occur or require divergent adhesion molecules. “?” indicates unknown data (4, 145).
Figure 4Mechanisms of formation and engagement of tethers and slings by rolling neutrophils. Rolling neutrophils experience high shear stress in the blood stream and have to overcome tensile stretch due to rolling. When PMNs converge into a blood vessel wall, the shear stress of the blood leads to cell flattening. PMNs limit stress forces during the rolling process by adhesive bonds generated at the front and disrupted at the rear of the PMN (4). At low detachment forces, these adhesive P-selectin-PSGL-1 bonds behave like catch bonds. With increasing force, the bonds become stronger, and long membrane bonds called tethers are created at the rear of the PMN (153, 154). The tethers bind to endothelial P−selectin via PSGL-1, forming temporary anchorage points that are subsequently disconnected from the endothelium by the pulling of tethers (4, 155). Once the tethers break at the rear of the rolling PMN, they swing forward and wrap around the cell as a sling, thereby decelerating the PMN. On slings, multiple patches along the whole projection are formed via the binding of PSGL-1 to the endothelium. This sequential attachment and pulling apart is referred to as the “step-wise peeling of slings”. The final deceleration and arrest of the cell results from the interaction of neutrophil LFA-1 with endothelial ICAM-2, leading to an even tighter wrapping of the sling around the cell body (4, 123).
Figure 5Overview of the different types of migration known for PMNs so far.
Figure 6Overview of the most important immune effects PMNs perform within the first line defense of the innate immune system.
Figure 7(A, B) Graphical presentation of the chronological sequence of the neutrophil immune effects ROS production and NETosis. Fluorescence images of an in vitro chemotaxis experiment with human PMNs: The cells were embedded in a type I collagen matrix and exposed to an fMLP gradient. ROS production was visualized using dihydrorhodamine 123 (red). NETosis was assessed with 4´,6-diamidino-2-phenylindole (DAPI, blue). The time points in the headlines of the images refer to the time of first gel contact. Overview of the sequence of neutrophil immune effects ROS production and NETosis in in-vitro-chemotaxix experiment (x40 magnification).
| APC | Antigen presenting cell |
| ARDS | Acute Respiratory Distress Syndrome |
| ARG-1 | Arginase 1 |
| BBB | Blood-brain-barrier |
| BLT1 | Leukotriene B4 receptor 1 |
| C5a | Activated complement factor 5 |
| CCL | Chemokine (C-C motif) ligand |
| CD | Cluster of differentiation |
| CINC-1 | Cytokine-induced neutrophil chemoattractant 1 |
| CNS | Central nerve system |
| COVID-19 | Coronavirus-induced disease 2019 |
| CTLD | C-type lectin domain |
| CXCL | Chemokine (C-X-C motif) ligand |
| DAMP | Damage-associated molecular pattern |
| DAPI | 4′,6-Diamidin-2-phenylindol |
| DHR | 1,2,3-Dihydrorhodamin |
| DIC | Disseminated intravascular coagulation |
| DNA | Desoxyribonucleic acid |
| DPEP-1 | Dipeptidase 1 |
| EC | Endothelial cell |
| ECM | Extracellular matrix |
| ECMO | Extracorporeal membrane oxygenation |
| ELAM-1 | Endothelial-leukocyte adhesion molecule 1 |
| ENA-78 | Epithelial-derived neutrophil-activating peptide 78 |
| ERK | Extracellular signal-regulated kinases |
| ESL-1 | E-selectin-ligand-1 |
| FGF2 | Fibroblast growth factor 2 |
| fMLP |
|
| FPR | Formyl peptide receptor |
| GAG | Glycosaminoglycane |
| G-CSF | Granulocyte colonization stimulating factor |
| GlyCAM | Glycosylation-dependent cellular adhesion molecule |
| GM-CSF | Granulocyte macrophage colony-stimulating factor |
| G-MDSC | Peripheral neutrophils and granulocytic Myeloid Derived Suppressor Cell |
| GPC(R) | G-protein-coupled receptor |
| GRO | Growth-regulated protein |
| H2O2 | Hydrogen peroxide |
| HA | Hyaluronic acid |
| HIF-1a | Hypoxia-inducible factor-1a |
| HLA–DR | Human leukocyte antigen DR |
| HOCl | Hypochlorous acid |
| ICAM | Intercellular adhesion molecule |
| IFN- γ | Interferon-γ |
| IL-8 | Interleukin 8 |
| JAM | Junctional adhesion molecule |
| LFA-1 | Lymphocyte function-associated antigen 1 |
| LPS | Lipopolysaccharide |
| LSALT | Synthetic peptide H-LSALTPSPSWLKYKAL-NH |
| LTB4 | Leukotriene B4 |
| MAC-1 | Macrophage antigen 1 |
| MAPK | Mitogen-activated protein kinases |
| MCP-1 | Monocyte chemoattractant protein 1 |
| MIF | Macrophage migration inhibitory factor |
| MIP-2 | Macrophage inflammatory protein 2 |
| MMP | Matrix metalloproteinase |
| MPO | Myeloperoxidase |
| MT | Microtubule |
| MTOC | Microtubule Organizing Center |
| NADPH | Nicotinamide adenine dinucleotide phosphate |
| NAP-2 | Neutrophil-activating peptide 2 |
| NE | Neutrophil elastase |
| NET | Neutrophil extracellular trap |
| OH• | Hydroxyl radical |
| PAD4 | Peptidyl arginine deiminase 4 |
| PAF | Platelet activating factor |
| PAFR | Platelet activating factor receptor |
| PAMP | Pathogen-associated molecular pattern |
| PD-1 | Programmed cell death protein 1 |
| PDL–1 | Programmed cell death ligand 1 |
| PECAM-1 | Platelet endothelial cell adhesion molecule 1 |
| PG | Pyoderma gangrenosum |
| PGP | Proline-glycine-proline |
| PI3K | Phosphoinositide 3-kinase |
| PKC | Protein kinase C |
| PMA | Phorbol 12-myristate 13-acetate |
| PMN | Polymorphonuclear cell |
| PRR | Pattern recognition receptors |
| PSGL-1 | P-selectin glycoprotein ligand 1 |
| PTX-3 | Pentraxin 3 |
| RA | Rheumatoid arthritis |
| rAC | Reverse abluminal crawling |
| RANTES | Chemokine regulated upon activation normal T-cell expressed and secreted |
| rIM | Reverse interstitial migration |
| ROS | Reactive oxygen species |
| rTEM | Reverse transendothelial migration |
| SDF-1 | Stromal cell-derived factor-1 |
| SFK | Redox-Src family kinase signaling |
| SLE | Systemic lupus erythematodes |
| SRC | Proto-oncogene tyrosine-protein kinase SRC |
| TAN | Tumor associated neutrophil |
| TME | Tumor micro-environment |
| TNF–α | Tumor necrosis factor α |
| TTCS | Tumor-tissue-culture-supernatants |
| VCAM–1 | Vascular cell adhesion protein 1 |
| VE-cadherin | Vascular endothelial cadherin |
| VEGFA | Vascular endothelial growth factor A |
| VWF | Von Willebrand factor |